Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

被引:499
|
作者
Ogitani, Yusuke [1 ]
Hagihara, Katsunobu [2 ]
Oitate, Masataka [2 ]
Naito, Hiroyuki [3 ]
Agatsuma, Toshinori [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan
关键词
Antibody-drug conjugate; bystander killing; HER2; T-DM; topoisomerase I inhibitor; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; CATHEPSIN-B; EXPRESSION; LYMPHOMA; THERAPY; PHASE-3; SAFETY;
D O I
10.1111/cas.12966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression. In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1. We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability. Under a coculture condition of HER2-positive KPL-4 cells and negative MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER2-positive NCI-N87 cells and HER2-negative MDA-MB-468-Luc cells by using an in vivo imaging system. In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not. Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is observed only in cells neighboring HER2-positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.
引用
收藏
页码:1039 / 1046
页数:8
相关论文
共 50 条
  • [1] Human epidermal growth factor receptor 2-positive digestive tumors
    Wagner, Anna D.
    Ozdemir, Berna C.
    Rueschoff, Josef
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (04) : 354 - 361
  • [2] Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors
    Menezes, Bruna
    Linderman, Jennifer J.
    Thurber, Greg M.
    DRUG METABOLISM AND DISPOSITION, 2022, 50 (01) : 8 - 16
  • [3] Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging Challenges and Opportunities
    Ducharme, Maxwell
    Mansur, Ameer
    Sligh, Luke
    Ulaner, Gary A.
    Lapi, Suzanne E.
    Sorace, Anna G.
    PET CLINICS, 2023, 18 (04) : 543 - 555
  • [4] Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers
    Yu, Jinfeng
    Fang, Tong
    Yun, Chengyu
    Liu, Xue
    Cai, Xiaoqing
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [5] New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer
    Britten, Karissa
    McAndrew, Nicholas
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2024, 36 (01) : 34 - 39
  • [6] Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
    Yao, Herui
    Yan, Min
    Tong, Zhongsheng
    Wu, Xinhong
    Ryu, Min-Hee
    Park, John J.
    Kim, Jee Hyun
    Zhong, Yahua
    Zhao, Yiming
    Voskoboynik, Mark
    Yin, Yongmei
    Liu, Kan
    Kaubisch, Andreas
    Liu, Caigang
    Zhang, Jian
    Wang, Shouman
    Im, Seock-Ah
    Ganju, Vinod
    Barve, Minal
    Li, Hui
    Ye, Changsheng
    Roy, Amitesh C.
    Bai, Li-Yuan
    Yen, Chia-Jui
    Gu, Shanzhi
    Lin, Yung-Chang
    Wu, Lingying
    Bao, Lequn
    Zhao, Kaijing
    Shen, Yu
    Rong, Shangyi
    Zhu, Xiaoyu
    Song, Erwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (29)
  • [7] Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer
    Gogia, Ajay
    Nigade, Jagdish
    Desai, Chirag
    Govind, Babu K.
    Deshmukh, Chetan
    Swarup, Binay
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2018, 39 (01) : 79 - 87
  • [8] Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity
    Grigg, Claud M.
    Livasy, Chad
    He, Jiaxian
    Hartman, Aaron
    Clark, Peter E.
    Zhu, Jason
    Raghavan, Derek
    Burgess, Earle F.
    HUMAN PATHOLOGY, 2021, 107 : 96 - 103
  • [9] Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review
    Zhang, Xiao
    Zhang, Xin-Ji
    Zhang, Tian-Yi
    Yu, Fei-Fei
    Wei, Xin
    Li, Ye-Sheng
    He, Jia
    BMC CANCER, 2014, 14
  • [10] Expression of Human Epidermal Growth Factor Receptor 2 in Meningiomas
    Ramezani, Mazaher
    Firoozabadi, Hanieh
    Rezaei, Mansour
    Khazaei, Sedigheh
    Sadeghi, Masoud
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (01) : 15 - 18